Clinical trials: Cancer of the Fallopian Tube
Ovarian Cancer, Fallopian Tube Cancer
SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care
This research study is testing the use of a smartphone app to identify clinically meaningful changes in the behaviors of patients' with gynecological cancers by using passively collected smartphone data.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
- Trial name
- SIGNAL (NCT04368130)
- Testing
- SIGNAL
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma of the Ovary, Fallopian Tube Cancer
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA…
- Conditions
- Carcinoma of the Ovary, Fallopian Tube Cancer, Peritoneal Serous-type Advanced Stage
- Trial name
- miRSa (NCT01391351)
- Testing
- blood samples
- Where
- 7 sites in France
- Volunteers
- 107 people
- Sponsor
- Centre Francois Baclesse
Ovarian Cancer, Fallopian Tube Neoplasms
Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response
The purpose of this study is to use an immunologic approach following the treatment for recurrent disease in patients with ovarian, fallopian tube, or peritoneal cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00103545
- Testing
- ACA 125
- Where
- 11 sites in Germany
- Volunteers
- 36 people
- Sponsor
- AGO Study Group
Fallopian Tube Cancer, Ovarian Cancer
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004012
- Testing
- capecitabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Peritoneal Cancer
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
The purpose of this study is to determine the effects (good and bad) the combination of carboplatin and pemetrexed have on patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00230542
- Testing
- Carboplatin, Pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Dana-Farber Cancer Institute
Fallopian Tube Cancer, Ovarian Cancer
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003636
- Testing
- carboplatin, cisplatin, conventional surgery
- Where
- 65 sites in Argentina, Austria and 13 more
- Volunteers
- 704 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bowel Obstruction, Ovarian Cancer
Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer
Ovarian cancer can often grow and cause obstructions in the bowel. These obstructions usually cannot be removed with surgery and can be fatal.
- Conditions
- Bowel Obstruction, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- CEBOC (NCT07648745)
- Testing
- Cediranib
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Prof Gordon Jayson
Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma
A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer
The investigators aimed to evaluate the safety of weekly paclitaxel with oncothermia and weekly cisplatin with oncothermia in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal…
- Conditions
- Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- POPOPO (NCT02344095)
- Testing
- weekly paclitaxel, weekly cisplatin, oncothermia
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Ovarian Cancer, Peritoneal Cancer
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT05071937
- Testing
- ZEN003694, Talazoparib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Alexander B Olawaiye, MD
Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
This is a Phase II study. The purpose of this study is to find out what effects, good and/or bad enzalutamide has on the patient and the cancer. All patients who enter the study will be closely monitored for side-effects.
- Conditions
- Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma
- Trial name
- NCT01974765
- Testing
- Enzalutamide
- Where
- 6 sites in United States
- Volunteers
- 59 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00217529
- Testing
- pegfilgrastim, carboplatin, docetaxel
- Where
- 3 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Hormone Receptor-Positive Breast, Gynecologic
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Background: Some types of cancer cells that have hormone receptors on their surfaces need the hormone estrogen to grow. The drug tamoxifen blocks estrogen from binding to the tumor cells, which helps to slow or stop the growth of…
- Conditions
- Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
- Trial name
- NCT01273168
- Testing
- Z-Endoxifen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum…
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
- Trial name
- NCT00421889
- Testing
- belinostat, Paclitaxel, Carboplatin
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 80 people
- Sponsor
- Valerio Therapeutics
Ovarian Cancer, Carcinoma, Ovarian Epithelial
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation…
- Conditions
- Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
- Trial name
- NCT05116189
- Testing
- Pembrolizumab, Paclitaxel, Bevacizumab
- Where
- 187 sites in United States, Australia and 23 more
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
Genital Neoplasms, Female, Fallopian Tube Neoplasms
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
This is a phase III randomized study comparing induction treatments of Gemcitabine and Carboplatin versus Paclitaxel and Carboplatin, with or without consolidation therapy for patients that do not have any evidence of disease…
- Conditions
- Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms
- Trial name
- NCT00191646
- Testing
- Gemcitabine, Paclitaxel, Carboplatin
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 919 people
- Sponsor
- Eli Lilly and Company
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor
Collecting Tumor Samples From Patients With Gynecological Tumors
This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in…
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
- Trial name
- NCT00897442
- Testing
- Laboratory Biomarker Analysis
- Where
- 187 sites in United States
- Volunteers
- 275 people
- Sponsor
- Gynecologic Oncology Group
Cervical Carcinoma, Fallopian Tube Carcinoma
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for…
- Conditions
- Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm
- Trial name
- NCT06492070
- Testing
- Best Practice, Cilostazol, Cryocompression Therapy
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Ovarian Cancer, Endometrial Cancer
Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers
Rationale: The administration of prophylactic G-CSF may reduce the toxicity of a weekly paclitaxel/carboplatin regimen in gynaecological cancers.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Uterine Cervical Cancer
- Trial name
- NCT01523678
- Testing
- Filgrastim, Paclitaxel, Carboplatin
- Where
- 17 sites in Belgium
- Volunteers
- 108 people
- Sponsor
- Belgian Gynaecological Oncology Group
Ovarian Cancer, Ovarian Neoplasms
A Trial of Vigil for Participants With Ovarian Cancer
The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo.
- Trial name
- VITAL (NCT02346747)
- Testing
- Vigil
- Where
- 26 sites in United States
- Volunteers
- 92 people
- Sponsor
- Gradalis, Inc.